Drug Profile
Research programme: PTEN modulators - Semafore Pharmaceuticals
Alternative Names: PTEN inhibitors research programme - SemaforeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Semafore Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced damage; Radiation injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy induced damage (Prevention) in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Radiation injuries (Prevention) in USA